[go: up one dir, main page]

PE20141031A1 - Composicion farmaceutica oftalmologica topica que contiene regorafenib - Google Patents

Composicion farmaceutica oftalmologica topica que contiene regorafenib

Info

Publication number
PE20141031A1
PE20141031A1 PE2013002872A PE2013002872A PE20141031A1 PE 20141031 A1 PE20141031 A1 PE 20141031A1 PE 2013002872 A PE2013002872 A PE 2013002872A PE 2013002872 A PE2013002872 A PE 2013002872A PE 20141031 A1 PE20141031 A1 PE 20141031A1
Authority
PE
Peru
Prior art keywords
pharmaceutical composition
composition containing
ophthalmological pharmaceutical
topical ophthalmological
refers
Prior art date
Application number
PE2013002872A
Other languages
English (en)
Inventor
Michael Bottger
Degenfeld Georges Von
Julia Freundlieb
Claudia Hirth-Dietrich
Joerg Keldenich
Jurgen Klar
Uwe Muenster
Andreas Ohm
Annett Richter
Bernd Riedl
Original Assignee
Bayer Healthcare Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=46456546&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PE20141031(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Bayer Healthcare Llc filed Critical Bayer Healthcare Llc
Publication of PE20141031A1 publication Critical patent/PE20141031A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4412—Non condensed pyridines; Hydrogenated derivatives thereof having oxo groups directly attached to the heterocyclic ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/12—Ophthalmic agents for cataracts

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Ophthalmology & Optometry (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Inorganic Chemistry (AREA)
  • Dispersion Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)

Abstract

SE REFIERE A UNA COMPOSICION FARMACEUTICA OFTALMOLOGICA TOPICA QUE COMPRENDE REGORAFENIB, QUE ES LA METILAMIDA DEL ACIDO 4{4-[3-(4-CLORO-3-TRIFLUOROMETILFENIL)-UREIDO]-3-FLUOROFENOXI}PIRIDIN-2-CARBOXILICO; UN HIDRATO; SOLVATO; POLIMORFO DEL MISMO Y UN VEHICULO FARMACEUTICAMENTE ACEPTABLE; DONDE EL AGENTE ACTIVO ESTA EN FORMA SOLIDA, CRISTALINA O MICROCRISTALINO. TAMBIEN SE REFIERE A UN PROCESO PARA FABRICAR DICHA COMPOSICION. SIENDO UTIL PARA EL TRATAMIENTO DE LA DEGENERACION MACULAR RELACIONADA CON LA EDAD (AMD), NEOVASCULARIZACION COROIDEA (CNV), ENTRE OTROS.
PE2013002872A 2011-06-28 2012-06-26 Composicion farmaceutica oftalmologica topica que contiene regorafenib PE20141031A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP11171719 2011-06-28
EP12155281 2012-02-14

Publications (1)

Publication Number Publication Date
PE20141031A1 true PE20141031A1 (es) 2014-08-21

Family

ID=46456546

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2013002872A PE20141031A1 (es) 2011-06-28 2012-06-26 Composicion farmaceutica oftalmologica topica que contiene regorafenib

Country Status (26)

Country Link
US (1) US20140296301A1 (es)
EP (1) EP2726059A1 (es)
JP (1) JP5998213B2 (es)
KR (1) KR20140048218A (es)
CN (1) CN103889399A (es)
AP (1) AP2013007335A0 (es)
AR (1) AR086800A1 (es)
AU (1) AU2012277905A1 (es)
BR (1) BR112013033831A2 (es)
CA (1) CA2840329A1 (es)
CL (1) CL2013003700A1 (es)
CO (1) CO6920289A2 (es)
CR (1) CR20130693A (es)
CU (1) CU24163B1 (es)
DO (1) DOP2013000314A (es)
EA (1) EA201400064A1 (es)
EC (1) ECSP13013106A (es)
GT (1) GT201300322A (es)
HK (1) HK1197176A1 (es)
MX (1) MX2013015287A (es)
PE (1) PE20141031A1 (es)
PH (1) PH12013502691A1 (es)
TN (1) TN2013000533A1 (es)
UY (1) UY34166A (es)
WO (1) WO2013000917A1 (es)
ZA (1) ZA201400646B (es)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2387812T3 (es) 2004-09-29 2012-10-02 Bayer Pharma Aktiengesellschaft Forma termodinámicamente estable del tosilato BAY 43-9006
AR081060A1 (es) 2010-04-15 2012-06-06 Bayer Schering Pharma Ag Procedimiento para preparar 4-{4-[({[4-cloro-3-(trifluorometil)fenil]amino}carbonil)amino]-3-fluorofenoxi}-n-metilpiridin-2-carboxamida
UY35183A (es) * 2012-12-21 2014-07-31 Bayer Healthcare Llc Composición farmacéutica oftalmológica tópica que contiene regorafenib
WO2015011659A1 (en) * 2013-07-24 2015-01-29 Dr. Reddys Laboratories Limited Crystalline polymorphic forms of regorafenib and processes for the preparation of polymorph i of regorafenib
CN103923000A (zh) * 2014-01-29 2014-07-16 苏州晶云药物科技有限公司 几种新晶型及其制备方法
CN104546776B (zh) * 2015-02-10 2017-08-22 杭州朱养心药业有限公司 瑞戈非尼片剂药物组合物和制法
EP3302379B1 (en) * 2015-06-06 2023-11-22 Cloudbreak Therapeutics, LLC Compositions and methods for treating pterygium
BR112018074454A2 (pt) 2016-06-02 2019-03-19 Cloudbreak Therapeutics, Llc composições e métodos de uso de nintedanib para tratar doenças oculares com neovascularização anormal

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2732222B1 (fr) * 1995-03-28 1997-04-25 Oreal Utilisation d'un antagoniste de cgrp pour le traitement des prurits et des dysesthesies oculaires et palpebraux
PT2020243T (pt) * 2002-05-28 2018-11-09 Astrazeneca Ab Preparação farmacêutica para uso tópico
US8637553B2 (en) * 2003-07-23 2014-01-28 Bayer Healthcare Llc Fluoro substituted omega-carboxyaryl diphenyl urea for the treatment and prevention of diseases and conditions
WO2006121963A2 (en) 2005-05-10 2006-11-16 Alcon, Inc. Suspension formulations comprising an active principle, a poloxamer or meroxapol surfactant and a glycol, its use for the manufacture of a medicament for treating ophthalmic disorders
US20060292203A1 (en) 2005-06-08 2006-12-28 Targegen, Inc. Methods and compositions for the treatment of ocular disorders
EP2329821B1 (en) 2005-11-29 2012-08-22 GlaxoSmithKline LLC Treatment of ocular neovascular disorders such as macular degeneration, angiod streaks, uveitis and macular edema
EP1962828A1 (en) * 2005-12-15 2008-09-03 Bayer HealthCare AG Diaryl urea for treating inflammatory skin, eye and/or ear diseases
JP2009521493A (ja) 2005-12-23 2009-06-04 アルコン，インコーポレイテッド 眼への受容体チロシンキナーゼ阻害（ＲＴＫｉ）化合物の送達のための医薬製剤
WO2008027341A2 (en) 2006-08-30 2008-03-06 Merck & Co., Inc. Topical ophthalmic formulations
AR062927A1 (es) 2006-10-11 2008-12-17 Bayer Healthcare Ag 4- [4-( [ [ 4- cloro-3-( trifluorometil) fenil) carbamoil] amino] -3- fluorofenoxi) -n- metilpiridin-2- carboxamida monohidratada
CN101678006A (zh) * 2007-05-11 2010-03-24 参天制药株式会社 含有非麦角类的选择性d2受体激动剂作为有效成分的后眼部疾病的预防或治疗剂
DE102007055341A1 (de) * 2007-11-19 2009-05-20 Bayer Animal Health Gmbh Stabilisierung öliger Suspensionen enthaltend hydrophobe Kieselsäuren
EP2432476A4 (en) 2009-05-01 2013-03-20 Ophthotech Corp METHOD FOR THE TREATMENT OR PREVENTION OF EYE DISEASES
BR112012001030A2 (pt) 2009-07-16 2019-09-24 Glaxo Wellcome Mfg Pte Ltd método para tratar a degeneração macular, e, uso de um composto.

Also Published As

Publication number Publication date
CN103889399A (zh) 2014-06-25
JP2014518233A (ja) 2014-07-28
TN2013000533A1 (en) 2015-03-30
US20140296301A1 (en) 2014-10-02
AR086800A1 (es) 2014-01-22
MX2013015287A (es) 2014-03-31
WO2013000917A1 (en) 2013-01-03
CU20130168A7 (es) 2014-04-24
ZA201400646B (en) 2015-11-25
NZ619229A (en) 2016-04-29
PH12013502691A1 (en) 2017-08-23
HK1197176A1 (en) 2015-01-09
CR20130693A (es) 2016-05-02
CA2840329A1 (en) 2013-01-03
ECSP13013106A (es) 2014-01-31
EP2726059A1 (en) 2014-05-07
GT201300322A (es) 2014-11-13
KR20140048218A (ko) 2014-04-23
BR112013033831A2 (pt) 2017-02-14
CU24163B1 (es) 2016-03-31
CL2013003700A1 (es) 2014-07-18
UY34166A (es) 2013-01-31
EA201400064A1 (ru) 2014-05-30
AU2012277905A8 (en) 2014-01-30
DOP2013000314A (es) 2014-04-15
AP2013007335A0 (en) 2013-12-31
AU2012277905A1 (en) 2014-01-16
CO6920289A2 (es) 2014-04-10
JP5998213B2 (ja) 2016-09-28

Similar Documents

Publication Publication Date Title
PE20141031A1 (es) Composicion farmaceutica oftalmologica topica que contiene regorafenib
SG10201900504XA (en) Pharmaceutical composition comprising glutarimide derivatives and use thereof in the treatment of eosinophilic diseases
WO2012063237A3 (en) Buffered ophthalmic compositions and methods of use thereof
TN2013000275A1 (en) Indole compounds or analogues thereof useful for the treatment of age-related macular degeneration (amd)
EA201492290A1 (ru) Составы и способы для вагинальной доставки антипрогестинов
PH12015500460A1 (en) Coated pharmaceutical composition containing regorafenib
MX2015016421A (es) Derivados de pirazolo-pirrolidin-4-ona como inhibidores de bet y su uso en el tratamiento de enfermedades.
BR112014004447A2 (pt) bifenilcarboxamidas como inibidores de quinase rock
WO2013188273A8 (en) Topical ophthalmological pharmaceutical composition containing axitinib
WO2013188268A8 (en) Topical ophthalmological pharmaceutical composition containing pazopanib
BR112014010729A2 (pt) métodos para tratamento de ataques de gota
IN2015DN04311A (es)
MD4563B1 (ro) Produs de comicronizare cu conţinut de acetat de ulipristal
CO7170176A2 (es) Nuevo compuesto que tiene la capacidad para inhibir la enzima deshidrogenasa11b-hidroxiesteroide tipo 1(11b-hsd1) o sal farmaceúticamente aceptable del mismo, método para producir el mismo, y composición farmaceútica que contiene el mismo como ingrediente activo
PE20061390A1 (es) Formulaciones de acido hidroxamico suberoilanilida y procedimientos para la produccion de las mismas
BR112014004732A2 (pt) composto benzotiazolona
TN2015000280A1 (en) Topical Ophthalmological Pharmaceutical Composition containing Regorafenib
MX2020003697A (es) Formulaciones farmaceuticas que comprenden un agonista del receptor opioide como ingredientes activos, metodos de fabricacion y usos terapeuticos de las mismas.
WO2013188279A8 (en) Topical ophthalmological pharmaceutical composition containing cediranib
GR1008228B (el) Φαρμακευτικο σκευασμα περιεχον ενα διπλο αναστολεα επαναπροσληψης και μεθοδος για την παρασκευη αυτου
GR1007906B (el) Οφθαλμικο φαρμακευτικο σκευασμα περιεχον ενα αναστολεα καρβονικης ανυδρασης και μεθοδος για την παρασκευη αυτου
MX2014000870A (es) Composiciones farmaceuticas que comprenden 4-bromo-n-(imidazolidin -2-iliden)-1h-benzimidazol-5-amina para tratar enfermedades de la retina.
PE20130202A1 (es) Composicion para tratar tuberculosis en base a perclorato de 4-tioureido-iminometilpiridinio
HK1194739A (en) Heterocyclic compounds and uses thereof in the treatment of sexual disorders

Legal Events

Date Code Title Description
FD Application declared void or lapsed